Antifungal dosing in critically ill patients

Current Fungal Infection Reports

Volumn 4, Issue 2, 2010, Pages 78-86

  Bergman, Scott J ^a   Tyagi, Isha ^a   Ronald, Katie ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphotericin B; Anidulafungin; Antifungals; Caspofungin; Combinations; Critical care; Dose; Echinocandin; Fluconazole; Flucytosine; ICU; Itraconazole; Lipid formulations; Micafungin; Pharmacodynamics; Pharmacokinetics; Posaconazole; Triazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ABDOMINAL ABSCESS; ANAPHYLAXIS; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; BONE MARROW SUPPRESSION; CANDIDEMIA; CANDIDIASIS; CHILL; COCCIDIOIDOMYCOSIS; CRITICALLY ILL PATIENT; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NEPHROTOXICITY; OROPHARYNX CANDIDIASIS; PERITONITIS; PLEURISY; PYELONEPHRITIS; RECOMMENDED DRUG DOSE; REVIEW; RIGOR; SIDE EFFECT; SYSTEMIC MYCOSIS; VOMITING; ZYGOMYCOSIS;

EID: 79952141392     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-010-0012-z     Document Type: Review

References (51)

1. Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645. (Pubitemid 41233011)
2. Patel GP, Simon D, Scheetz M, et al.: The effect of time to antifungal therapy on mortality in candidemia associated septic shock. Am J Ther 2009, 16:508-511.
3. Pea F, Viale P, Furlanut M: Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005, 44:1009-1034. (Pubitemid 41356389)
4. Walsh TJ, Anaissie EJ, Denning DW, et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360. This article summarizes the evidence supporting the treatment of aspergillosis.
5. Lewis JS 2nd, Graybill JR: Fungicidal versus fungistatic: what's in a word? Expert Opin Pharmacother 2008, 9:927-935.
6. Wiederhold NP, Kontoyiannis DP, Chi J, et al.: Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004, 190:1464-1471. (Pubitemid 39332186)
7. Wagner C, Graninger W, Presterl E, Joukhadar C: The echinocandins: comparison of their pharmacokinetics, pharmacodynamics, and clinical applications. Pharmacology 2006, 78:161-177. (Pubitemid 44948055)
8. Mazzei T, Novelli A: Pharmacological properties of antifungal drugs with a focus on anidulafungin. Drugs 2009, 69(Suppl 1):79-90.
9. Constantin JM, Roszyk L, Guerin R, et al.: [Tolerance of caspofungin in intensive care unit: a prospective study] [in French]. Ann Fr Anesth Reanim 2008, 27(10):819-824.
10. Dowell JA, Knebel W, Ludden T, et al.: Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004, 44:590-598. (Pubitemid 38668021)
11. Gumbo T: Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies. Curr Opin Infect Dis 2007, 20:587-591.
12. Betts RF, Nucci M, Talwar D, et al.: A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009, 48:1676-1684. This is the first clinical study to compare two different doses of caspofungin. The group receiving 150 mg per day did not have better outcomes than the standard-dose group.
13. Gafter-Gvili A, Vidal L, Goldberg E, et al.: Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008, 83:1011-1021.
14. Dupont BF, Lortholary O, Ostrosky-Zeichner L, et al.: Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care 2009, 13:R159.
15. Mills EJ, Perri D, Cooper C, et al.: Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis. Ann Clin Microbiol Antimicrob 2009, 8:23.
16. Mora-Duarte J, Betts R, Rotstein C, et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029. (Pubitemid 35461658)
17. Reboli AC, Rotstein C, Pappas PG, et al.: Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482. This is the first study to show a difference in outcomes for an echinocandin. Although the difference did not remain statistically significant 6 weeks after the end of therapy, fewer patients died while receiving anidulafungin.
18. Pappas PG, Rotstein CM, Betts RF, et al.: Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893. This is the first clinical trial to demonstrate that there is no difference between micafungin (100 or 150 mg/d) and caspofungin.
19. Pfaller MA, Boyken L, Hollis RJ, et al.: In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008, 46:150-156.
20. Perlin DS: Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007, 10:121-130.
21. Pappas PG, Kauffman CA, Andes D, et al.: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. This is a summary of the evidence supporting treatments for candidiasis.
22. Mohr J, Johnson M, Cooper T, et al.: Current options in antifungal pharmacotherapy. Pharmacotherapy 2008, 28:614-645. (Pubitemid 351620030)
23. Thompson GR 3rd, Cadena J, Patterson TF: Overview of antifungal agents. Clin Chest Med 2009, 30:203-215.
24. Lewis RE: Pharmacodynamic implications for use of antifungal agents. Curr Opin Pharmacol 2007, 7:491-497.
25. Pennisi M, Antonelli M: Clinical aspects of invasive candidiasis in critically ill patients. Drugs 2009, 69(Suppl 1):21-28.
26. Connor H, Bergman S: Candida susceptibility to fluconazole [abstract 1-131]. Presented at American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV; December 5-10, 2009.
27. Galgiani JN, Ampel NM, Blair JE, et al.: Coccidioidomycosis. Clin Infect Dis 2005, 41:1217-1223. (Pubitemid 41532662)
28. Perfect JR, Dismukes WE, Dromer F, et al.: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50(3):291-322. This article summarizes the evidence supporting treatments for cryptococcal disease.
29. Pappas PG, Chetchotisakd P, Larsen RA, et al.: A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2009, 48:1775-1783.
30. Longley N, Muzoora C, Taseera K, et al.: Dose-response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008, 47:1556-1561.
31. Silling G: Fluconazole: optimized antifungal therapy based on pharmacokinetics. Mycoses 2002, 45(Suppl 3):39-41.
32. Bergman SJ, Speil C, Short M, Koirala J: Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations. Infect Dis Clin North Am 2007, 21:821-846. (Pubitemid 47362604)
33. Baddley JW, Patel M, Bhavnani SM, et al.: Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008, 52:3022-3028. This study led to the establishment of an AUC/MIC ≥25 as the pharmacodynamic parameter most associated with efficacy.
34. Garey KW, Pai MP, Suda KJ, et al.: Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007, 16:919-927. (Pubitemid 47322590)
35. Lipp HP: Antifungal agents - clinical pharmacokinetics and drug interactions. Mycoses 2008, 51(Suppl 1):7-18.
36. Heintz BH, Matzke GR, Dager WE: Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009, 29:562-577. This good review article gives dosing recommendations for renal replacement therapy in critically ill adults.
37. Bruggemann RJ, Alffenaar JW, Blijlevens et al.: Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009, 48:1441-1458. This is another good review article, which discusses managing dosing for triazoles, along with their many drug-drug interactions.
38. Nivoix Y, Leveque D, Herbrecht R, et al.: The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008, 47:779-792.
39. Smith J, Andes D: Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008, 30:167-172. This article reviews when it may be necessary to conduct therapeutic drug monitoring for antifungals and why, and it discusses what concentrations to expect in patients in order to achieve efficacy and prevent toxicity.
40. Andes D, Safdar N, Marchillo K, Conklin R: Pharmacokinetic- pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006, 50:674-684. (Pubitemid 43190982)
41. Lewis RE, Wiederhold NP: The solubility ceiling: a rationale for continuous infusion amphotericin B therapy? Clin Infect Dis 2003, 37:871-872.
42. Dismukes WE: Antifungal therapy: lessons learned over the past 27 years. Clin Infect Dis 2006, 42:1289-1296.
43. Alvarez-Lerma F, Mariscal F, Quintana E, et al.: Use of liposomal amphotericin B in critically ill patients: a retrospective, multicenter, clinical study. J Chemother 2009, 21:330-337.
44. Bicanic T, Wood R, Meintjes G, et al.: High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008, 47(1):123-130. (Pubitemid 351920599)
45. Petrikkos GL: Lipid formulations of amphotericin B as firstline treatment of zygomycosis. Clin Microbiol Infect 2009, 15 (Suppl 5):87-92. This is the largest study to date of patients with zygomycosis treated with the lipid formulations of amphotericin B.
46. Pasqualotto AC: Amphotericin B: the higher the dose, the higher the toxicity [comment]. Clin Infect Dis 2008, 47:1110; author reply 1110-1111.
47. Moen MD, Lyseng-Williamson KA, Scott LJ: Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009, 69:361-392.
48. Hamill RJ, Sobel J, El-Sadr W, et al.: Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphothericin B in acute cryptococcal meningitis in AIDS patients [abstract 1161]. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (organized by the American Society of Microbiology). San Francisco, CA; 1999.
49. Cornely OA, Maertens J, Bresnik M, et al.: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44:1289-1297. A regimen with 10 mg/kg loading doses over 2 weeks showed substantially more toxicity than 3 mg/kg, without greater efficacy.
50. Brouwer AE, Rajanuwong A, Chierakul W, et al.: Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004, 363:1764-1767. (Pubitemid 38698379)
51. Milefchik E, Leal MA, Haubrich R, et al.: Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008, 46:393-395. (Pubitemid 351552497)